<strong>Background:</strong><span style="white-space:normal;font-family:;" "=""> Long</span><span style="white-space:normal;font-family:;" "=&quo...<strong>Background:</strong><span style="white-space:normal;font-family:;" "=""> Long</span><span style="white-space:normal;font-family:;" "="">-</span><span style="white-space:normal;font-family:;" "="">term survival in acute coronary syndrome has increased steadily in the last decades. Follow-up studies developed in this patient clearly reveal that they are at risk of suffering a new event, placing them in a new stage, secondary prevention. Assuming this increased risk, the control target of their cardiovascular risk factors become more ambitious. In this field, control of Cholesterol levels, particularly LDL-C, ha</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> arisen as a priority objective in patients with coronary arterial disease. In this sense, management of </span><span style="white-space:normal;font-family:;" "="">dyslipidemia </span><span style="white-space:normal;font-family:;" "="">guidelines, recently recognise</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> the role of functional food, highlighting among them </span><span style="white-space:normal;font-family:;" "="">is </span><span style="white-space:normal;font-family:;" "="">the Red Yeast Rice (RYR). The aim of the study is to establish the potential role of functional food, in secondary prevention</span><span style="white-space:normal;font-family:;" "="">,</span><span style="white-space:normal;font-family:;" "=""> while deter</span><span style="white-space:normal;font-family:;" "="">mining its additional capacity to reduce LDL-C in patients that despite optimal classic treatment (maximum tolerated dose of stain plus Ezetimibe) </span><span style="white-space:normal;font-family:;" "="">is</span><span style="white-space:normal;font-family:;" "=""> still out of control objectives. <b>Results and Discussion:</b> 88 patients were included and after 3 months of treatment with RYR, their lipid profiles were compared with the baseline. The variation of T-Col, LDL-C and Trig were statistically significant. A reduction in LDL-C was 10.73</span><span style="white-space:normal;font-family:;" "=""> </span><span style="white-space:normal;font-family:;" "="">mg/dL, which means a 10.93% of additional reduction over the standard therapy the patients were receiving. Concerning security, no relevant side effects were reported when adding RYR, even in a relevant percentage (35.4%)</span><span style="white-space:normal;font-family:;" "="">,</span><span style="white-space:normal;font-family:;" "=""> myalgia disappeared (especially when reduc</span><span style="white-space:normal;font-family:;" "="">ing the </span><span style="white-space:normal;font-family:;" "="">titrating dose </span><span style="white-space:normal;font-family:;" "="">of </span><span style="white-space:normal;font-family:;" "="">the statin). <b>Conclusion:</b> Adding</span><span style="white-space:normal;font-family:;" "=""> RYR in secondary prevention patients in combination with the usual treatment, seems </span><span style="white-space:normal;font-family:;" "="">to be </span><span style="white-space:normal;font-family:;" "="">an effective alternative to optimi</span><span style="white-space:normal;font-family:;" "="">z</span><span style="white-space:normal;font-family:;" "="">e LDL levels and thus get</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> closer to the target set in the</span><span style="white-space:normal;font-family:;" "=""> </span><span style="white-space:normal;font-family:;" "="">guidelines, without adding relevant side effects, </span><span style="white-space:normal;font-family:;" "="">and </span><span style="white-space:normal;font-family:;" "="">even improving tolerance to the statins.</span>展开更多
文摘<strong>Background:</strong><span style="white-space:normal;font-family:;" "=""> Long</span><span style="white-space:normal;font-family:;" "="">-</span><span style="white-space:normal;font-family:;" "="">term survival in acute coronary syndrome has increased steadily in the last decades. Follow-up studies developed in this patient clearly reveal that they are at risk of suffering a new event, placing them in a new stage, secondary prevention. Assuming this increased risk, the control target of their cardiovascular risk factors become more ambitious. In this field, control of Cholesterol levels, particularly LDL-C, ha</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> arisen as a priority objective in patients with coronary arterial disease. In this sense, management of </span><span style="white-space:normal;font-family:;" "="">dyslipidemia </span><span style="white-space:normal;font-family:;" "="">guidelines, recently recognise</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> the role of functional food, highlighting among them </span><span style="white-space:normal;font-family:;" "="">is </span><span style="white-space:normal;font-family:;" "="">the Red Yeast Rice (RYR). The aim of the study is to establish the potential role of functional food, in secondary prevention</span><span style="white-space:normal;font-family:;" "="">,</span><span style="white-space:normal;font-family:;" "=""> while deter</span><span style="white-space:normal;font-family:;" "="">mining its additional capacity to reduce LDL-C in patients that despite optimal classic treatment (maximum tolerated dose of stain plus Ezetimibe) </span><span style="white-space:normal;font-family:;" "="">is</span><span style="white-space:normal;font-family:;" "=""> still out of control objectives. <b>Results and Discussion:</b> 88 patients were included and after 3 months of treatment with RYR, their lipid profiles were compared with the baseline. The variation of T-Col, LDL-C and Trig were statistically significant. A reduction in LDL-C was 10.73</span><span style="white-space:normal;font-family:;" "=""> </span><span style="white-space:normal;font-family:;" "="">mg/dL, which means a 10.93% of additional reduction over the standard therapy the patients were receiving. Concerning security, no relevant side effects were reported when adding RYR, even in a relevant percentage (35.4%)</span><span style="white-space:normal;font-family:;" "="">,</span><span style="white-space:normal;font-family:;" "=""> myalgia disappeared (especially when reduc</span><span style="white-space:normal;font-family:;" "="">ing the </span><span style="white-space:normal;font-family:;" "="">titrating dose </span><span style="white-space:normal;font-family:;" "="">of </span><span style="white-space:normal;font-family:;" "="">the statin). <b>Conclusion:</b> Adding</span><span style="white-space:normal;font-family:;" "=""> RYR in secondary prevention patients in combination with the usual treatment, seems </span><span style="white-space:normal;font-family:;" "="">to be </span><span style="white-space:normal;font-family:;" "="">an effective alternative to optimi</span><span style="white-space:normal;font-family:;" "="">z</span><span style="white-space:normal;font-family:;" "="">e LDL levels and thus get</span><span style="white-space:normal;font-family:;" "="">s</span><span style="white-space:normal;font-family:;" "=""> closer to the target set in the</span><span style="white-space:normal;font-family:;" "=""> </span><span style="white-space:normal;font-family:;" "="">guidelines, without adding relevant side effects, </span><span style="white-space:normal;font-family:;" "="">and </span><span style="white-space:normal;font-family:;" "="">even improving tolerance to the statins.</span>